Viewing nowHyundai Pregabalin Tablet 150mg
Pregabalin 150mg
Tablet · Prescription medication
Hyundai Pharmaceutical Co., Ltd.

MFDS item code 201800512 · Approved 2018.01.29 · Insurance code 642004180
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used to alleviate peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive therapy for partial seizures in patients with epilepsy to help control symptoms. Additionally, it effectively aids in the treatment of pain in patients with fibromyalgia. Collectively, this drug is used for the treatment of neuropathic pain, epilepsy, and fibromyalgia.
The total daily dose of this medicine, pregabalin, is administered orally in 2 divided doses, with or without food. 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg per day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased to 225 mg twice daily (450 mg per day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over a period of at least 1 week. 5. Patients with renal impairment Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = Divide the total daily dose into 3 doses BID = Divide the total daily dose into 2 doses QD = Administer once daily a: The total daily dose (mg/day) should be divided as indicated in the dosing frequency. b: The supplemental dose is a single additional dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication is an anticonvulsant, and during treatment, suicidal thoughts, suicidal behaviors, or symptoms of depression may occur or worsen, so both patients and caregivers should closely monitor for these changes. This medication must not be taken by anyone allergic to pregabalin or any of its components. Diabetic patients may experience weight gain while taking this medication, which may require adjustments to their blood sugar control medications. If swelling occurs in the face, mouth, or neck while taking this medication, it should be discontinued immediately and medical consultation sought. Elderly patients may experience symptoms such as dizziness, drowsiness, loss of consciousness, and confusion more frequently when taking this medication, so special caution is required at the start of treatment. This medication may cause blurred vision or changes in eyesight; any symptoms should be discussed with a healthcare professional. Caution is necessary when switching from another anticonvulsant medication to this medication as monotherapy. Abruptly stopping this medication may lead to withdrawal symptoms such as insomnia, headaches, nausea, anxiety, depression, and suicidal thoughts, thus it should be tapered off gradually according to a healthcare professional's instructions. Patients with a history of substance abuse are at higher risk of drug dependence or abuse when taking this medication, so caution is advised. Patients with reduced kidney function should have their doses adjusted, and those with heart failure should use caution as well. When taken with opioid analgesics, there is an increased risk of central nervous system depression; therefore, caution should be exercised. This medication can cause respiratory depression, and special care should be taken in patients with respiratory disorders, kidney issues, and the elderly. In the early stages of pregnancy, there may be a risk of congenital malformations in the fetus, so pregnant women should avoid taking this medication, and women of childbearing age should use effective contraception. Nursing mothers should consider that this medication is excreted in breast milk, thus it is recommended to discontinue nursing or the medication. This medication may cause dizziness and drowsiness, so symptoms should be monitored before performing tasks that require alertness, such as driving or operating hazardous machinery. Rarely, a severe allergic reaction or severe skin disorders may occur; if any skin abnormalities appear, the medication should be discontinued immediately. In the event of overdose, symptoms such as altered consciousness, depression, or seizures may occur; emergency measures such as hemodialysis may be necessary if needed. This medication should be kept out of reach of children and should not be transferred to other containers for safety reasons.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to protect it from air and moisture exposure. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature.
White or pale yellow round tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Tablet · Prescription medication
Hyundai Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.